Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24220982 | 0.93 | FOLH1 (0.44) | NPSR1TLR2MMENAAAKDM1A | |
| SCHEMBL24677819 | 0.88 | HTR2A (0.44) | NPSR1TLR2MMENAAAPOLB | |
| SCHEMBL23052535 | 0.86 | MME (0.43) | NPSR1TLR2MMENAAAPOLB | |
| SCHEMBL21081697 | 0.86 | MME (0.43) | NPSR1TLR2MMENAAAPOLB | |
| SCHEMBL22799503 | 0.81 | KDM1A (0.40) | NPSR1MMENAAAKDM1AMAOB | |
| SCHEMBL21081675 | 0.76 | HTR2A (0.47) | NPSR1MMENAAAKDM1AMAOB | |
| SCHEMBL21081698 | 0.76 | HTR2A (0.47) | NPSR1MMENAAAKDM1AMAOB | |
| SCHEMBL21081674 | 0.75 | ALDH1A1 (0.43) | NPSR1MMEPOLBALDH1A1 | |
| SCHEMBL21787144 | 0.75 | ALDH1A1 (0.43) | NPSR1MMEPOLBALDH1A1 | |
| SCHEMBL23052581 | 0.75 | KDM4E (0.42) | NPSR1TLR2MMEPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | ASTRAZENECA AB (SE) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | CD44, FOLH1, SLC17A5 | NPSR1 1085/4885TLR2 1643/4885MME 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.